Subsets of neurotensin-immunoreactive neurons revealed following antagonism of the dopamine-mediated suppression of neurotensin immunoreactivity in the rat striatum.
The distribution of neurotensin-immunoreactive structures in the rat striatum was evaluated after blockade of dopamine neurotransmission by drugs that act presynaptically (6-hydroxydopamine, reserpine) and postsynaptically, preferentially at the D2 (eticlopride, haloperidol) and D1 [(R)-(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepi n-7-ol, SCH-23390] receptor sites. Calbindin-D (mol. wt 28,000) immunoreactivity was used to delineate patch (striosome) and matrix in the caudate-putamen and core and shell in the nucleus accumbens. Antagonism at the D2 dopamine receptor and 6-hydroxydopamine lesions caused dense axonal immunoreactivity and moderate numbers of neurotensin-immunoreactive neurons to be distributed preferentially in the matrix of the caudate-putamen. D1 receptor antagonism was significantly less effective at eliciting neurotensin-immunoreactive neurons in the caudate-putamen. Reserpine or co-administration of the D1 and D2 receptor antagonists produced many neurotensin-immunoreactive neurons in both striatal compartments throughout the caudate-putamen and dense axonal neurotensin immunoreactivity in the medial patch compartment. To varying degrees, with SCH-23390 being least effective and reserpine most effective, all of the drug treatments elicited neurotensin immunoreactivity in neurons in the olfactory tubercle, rostral nucleus accumbens, accumbal shell and ventrolateral caudate-putamen, i.e. most of the ventral striatum.
Zahm
D S
DS
Department of Anatomy and Neurobiology, St Louis University School of Medicine, MO 63104.
D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D064026:Calbindins; D002421:Caudate Nucleus / Q000378:metabolism; D003342:Corpus Striatum / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D004298:Dopamine / Q000494:pharmacology; D018492:Dopamine Antagonists; D006220:Haloperidol / Q000494:pharmacology; D007150:Immunohistochemistry; D008297:Male; D009474:Neurons / Q000276:immunology / Q000378:metabolism*; D009496:Neurotensin / Q000276:immunology / Q000502:physiology*; D016627:Oxidopamine / Q000494:pharmacology; D011699:Putamen / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D064030:S100 Calcium Binding Protein G / Q000378:metabolism; D012457:Salicylamides / Q000494:pharmacology
D001552:Benzazepines; D064026:Calbindins; D018492:Dopamine Antagonists; D064030:S100 Calcium Binding Protein G; D012457:Salicylamides; D009496:Neurotensin; D016627:Oxidopamine; D006220:Haloperidol; C045989:eticlopride; D004298:Dopamine